We think that the visit to Italy has been satisfactory, the IFV Research Director, Dr. Dagmar Garcia, a member of the delegation, told Prensa Latina.
The group also includes Dr. Luis Herrera, scientific advisor to the president of BioCubaFarma and founder of the Center for Genetic Engineering and Biotechnology (CIGB).
We have discussed and presented the scientific results of the development of the Soberana 02 vaccine in children and appreciated the recognition of these results by different healthcare and scientific institutions with which we met, she indicated.
Among these, she mentioned the Italian Drug Agency, a national regulatory entity, in which, she pointed out, “we managed to better understand the regulatory mechanisms” so that a vaccine developed in Cuba enters the world regulated by the European Medicines Agency, “which are really very complex processes,” she said.
We are leaving with the mission of returning, once we better understand everything we have to do, we will return with new work proposals to Italy, the expert noted.
During its stay in Italy, the IFV delegation fulfilled commitments in the cities of Turin, Rome and Naples, including the presentation of the good results obtained by the Soberana Plus Turin clinical trial, developed in conjunction with the Amedeo di Savoia hospital in that city.
Among other events held in this capital, Dr. Vicente Verez bestowed a young scientist collaborating with the IFV, Fabrizio Chiodo, with the Carlos J. Finlay Order, the highest decoration in Cuba to personalities and institutions in field of sciences.
jg/mgt/fgg
